OOIR: Observatory of International Research

Papers

(The H4-Index of Trends in Pharmacological Sciences is 53. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-06-01 to 2026-06-01.)

Article	Citations
Subscription and Copyright Information	670
Shearing of surface mucin saps tumor cell strength	571
Subscription and Copyright Information	279
Advisory Board and Contents	245
Subscription and Copyright Information	245
Subscription and Copyright Information	219
Subscription and Copyright Information	206
DOT1L: orchestrating methylation-dependent radiotheRAPy responses via BRCA1	200
Structural asymmetry in FGF23 signaling	188
Muscarinic receptors: from clinic to bench to clinic	183
Cancer pathogenesis and phase targeting through condensate fragility	166
Monitoring neurodegeneration through brain-derived extracellular vesicles in biofluids	151
Swinging the SWI/SNF complexes for cancer therapy	147
Ensifentrine (Ohtuvayre™) for chronic obstructive pulmonary disease	140
Advancing chemical carcinogenicity prediction modeling: opportunities and challenges	139
Compstatins: the dawn of clinical C3-targeted complement inhibition	131
Targeting complement in neurodegeneration: challenges, risks, and strategies	125
Therapeutic inhibition of ferroptosis in neurodegenerative disease	114
Structural pharmacology and mechanisms of GLP-1R signaling	110
Advisory Board and Contents	106
Direct in vivo CAR T cell engineering	106
Leveraging human microbiomes for disease prediction and treatment	105
Engineering ACE2 decoy receptors to combat viral escapability	105
The B7-H3 (CD276) pathway: emerging biology and clinical therapeutics	104
Advisory Board and Contents	103

HSV-1 as a gene delivery platform for cancer gene therapy	101
Mechanistic considerations for adenosine-lidocaine-magnesium (ALM) in controlling coagulopathy	99
A smart hospital-driven approach to precision pharmacovigilance	95
Advisory Board and Contents	95
Programmable CAR immunotherapies for neurodegenerative proteinopathies	94
Chemically modified neoantigen-based immunotherapy for targeting KRASG12C-driven tumors	89
A deep dive into degrader-induced protein-protein interfaces	87
Phenotypic approaches for CNS drugs	87
A perspective on psychedelic teratogenicity: the utility of zebrafish models	85
Nemolizumab (Nemluvio®) for prurigo nodularis	84
Ribosome-directed cancer therapies: the tip of the iceberg?	76
Genetically engineered loaded extracellular vesicles for drug delivery	73
Optogenetic engineering for precision cancer immunotherapy	72
Subscription and Copyright Information	69
Thriving as members of under-represented groups in pharmacology-related careers	67
Emerging approaches to induce immune tolerance to therapeutic proteins	66
Mentoring future science leaders to thrive	66
Subscription and Copyright Information	66
Now you serine, now you don't	66
Subscription and Copyright Information	64
Alzheimer’s therapeutic development: shifting neurodegeneration to neuroregeneration	58
Deubiquitinating enzymes as therapeutic targets in diabetic nephropathy	58
The structure, function, and pharmacology of MRGPRs	58
GPR35, ally of the anti-ischemic ATPIF1-ATP synthase interaction	58
Advancing non-destructive analysis of 3D printed medicines	56
Bimetallic nanoadjuvants for cancer vaccines	56
Targeting AMPK as a potential treatment for hepatic fibrosis in MASLD	55
Piezo1: structural pharmacology and mechanotransduction mechanisms	55
Suzetrigine for moderate to severe acute pain	53